Skip to main content

CRO India for European Sponsors

  • Home
  • CRO India for European Sponsors

Clinical research, regulatory and compliance information from BioAgile Therapeutics.

Need Expert Help? We’re Just a Call Away.

In short: European sponsors can run clinical studies in India and use the data in an EU or EEA marketing authorisation application, as long as the trials meet the ethical and good clinical practice (GCP) requirements EU law sets for trials wherever they are conducted. BioAgile Therapeutics is a CDSCO-approved, ISO 9001:2015 certified CRO in Bengaluru that manages the India side of the study: Indian approvals, site conduct, data and reports.

What EU rules say about trials run outside Europe

The European Medicines Agency states that, regardless of where they are conducted, all clinical trials included in applications for marketing authorisation in the EU and EEA must have been carried out in accordance with the requirements in Annex I of Directive 2001/83/EC. In plain terms, the country of the study site does not exempt a trial from EU expectations on ethics and GCP, and it does not exclude the data either. Compliance is the test.

The EU Clinical Trials Regulation (Regulation (EU) No 536/2014) applies to the authorisation of trials in EU and EEA countries. Sponsors submit one application through the Clinical Trials Information System (CTIS), run by the EMA, from 31 January 2023 for all new trials. An India-only study is authorised in India, not through CTIS. A multinational programme combines the two: CTIS for the European countries, and CDSCO plus an ethics committee for India. We plan the India part so it fits the protocol you are filing in Europe.

Where your European regulator fits

Each country below assesses and supervises trials on its own territory through CTIS. Each link goes to the regulator’s own page.

CountryRegulatorWhat to know
GermanyBfArMApplications go through CTIS. BfArM states that a validated mononational trial application is assessed within 26 days, with authorisation by day 31 at the latest if there are no deficiencies.
FranceANSMANSM publishes the procedure for requesting authorisation of a clinical trial of medicines. Trials are submitted through CTIS.
ItalyAIFAAIFA publishes guidance on the European clinical trials regulation and on managing studies in CTIS.
DenmarkDanish Medicines AgencyAll trials are applied for in CTIS. Deadlines are fixed by the regulation and built into the system. The agency’s stated goal is to assess a valid mononational trial by day 26.
SwitzerlandSwissmedicOutside the EU. Separate rules apply (see below).

Switzerland is its own system

Switzerland is not part of the EU Clinical Trials Regulation. Swissmedic’s page explains that category B and C trials can be submitted in parallel to Swissmedic and the responsible ethics committee, and that each issues a separate approval. Category A trials with therapeutic products are exempt from Swissmedic’s authorisation requirement. New implementing ordinances have applied since 1 November 2024. If your programme includes Swiss sites as well as India, tell us early so the two timelines are planned together.

What BioAgile handles in India

Indian approvals

CDSCO permissions and ethics committee approval under the New Drugs and Clinical Trials Rules, 2019. See regulatory support.

Study conduct

Site selection, monitoring, safety reporting and project management. See clinical trials and BA/BE studies.

Data and statistics

Data management and biostatistics to a plan agreed before the first subject is enrolled. See data management and biostatistics.

Reports and quality

Clinical study reports in ICH E3 structure and audit-ready records. See medical writing and quality assurance.

Our overview of the Indian framework is on the CRO in India page. BioAgile holds CDSCO registration as a CRO (Reg. No. CRO/KA/2026/000173) and ISO 9001:2015 certification. If a specific audit or inspection record matters to your decision, ask us what we can document.

Working across time zones and languages

Indian office hours (9:30 am to 6:00 pm IST) overlap with the European morning, so regular calls with your team are possible within normal hours on both sides. We work in English. We agree a call schedule and a named project manager at kick-off.

Frequently asked questions

Can data from clinical studies in India support an EU marketing authorisation application?

Yes, if the trials meet the requirements of Annex I of Directive 2001/83/EC. The EMA says this applies regardless of where the trial is conducted.

Do I submit an India-only study through CTIS?

No. CTIS is the EU and EEA submission route for trials in those countries. A study in India is authorised in India. A programme with both European and Indian sites uses CTIS for the European part and CDSCO for India.

Is Switzerland covered by the EU Clinical Trials Regulation?

No. Swissmedic and the responsible ethics committee authorise trials under Swiss rules.

Does BioAgile manage the Indian regulatory submissions?

Yes. We handle CDSCO submissions and ethics committee approvals for the India part of your study.

Can we start by running a BA/BE study in India?

Yes. BA/BE studies are one of our core services. The design depends on your product and the regulatory strategy you are following in Europe. We plan it with you.

Official sources

Planning an India study for a European programme?

Tell us the product, the study type and which European regulator you are filing with. We will reply with a plan for the India side and the questions we need answered.

Contact our teamCall 080 4375 4520